Stanford researchers in Prof. Engleman and Reticker-Flynn's labs have created a novel cell therapy that targets the T-antigen, a prominent tumor-specific antigen, by leveraging the high avidity interactions between lectins and glycans.
Overweight and obesity are linked to an increased risk and worsened outcome from many cancers, including colorectal, pancreatic and breast cancer, but the mechanisms responsible for these phenomena are unknown.
Stanford researchers have defined subgroups of regulatory T cell (Tregs), CD39+ and CD39-, that can be genetically engineered to produce enhanced or reduced cytotoxicity without affecting their ability to suppress the immune system.
Researchers at Stanford University have discovered a first-in-class covalent inhibitor that binds to activated Fis1 and prevents mitochondrial fission and dysfunction.
Researchers at Stanford have developed fully genetically-encodable lysosome-targeting chimeras which allow for the targeted delivery of various proteins into receiver cells.
Stanford scientists have discovered that the untranslated region (UTR) of RNA can be engineered into autonomous switches capable of both sensing native biological conditions (e.g.
Stanford researchers have discovered using a novel assay that a large proportion of CRISPR/AAV modified cells contain hidden concatemeric knockins that affect gene expression, and therefore developed a strategy to reduce their occurrence.
The skin cells that line the esophagus are critical for protecting against the friction of food when we swallow. However, they can be damaged by genetic disorders, caustic burns, and surgical resections for cancer treatment.
Stanford scientists have developed cross-reactive antibodies that can bind human and murine NKp46 on NK cells and induce cytotoxicity and proliferation.
Type 1 regulatory T cells (Tr1s) are an inducible subtype of regulatory T cells that can play a beneficial (autoimmune diseases, allergy, hematological malignancies) or detrimental role (some solid tumors and infectious diseases) in human diseases. Tr1 cells.
Researchers at Stanford have developed a novel deep-learning-based tool called CytoTRACE2 that interprets single-cell RNA sequencing (scRNA-seq) to enable the discovery of regenerative cells across all tissue types and novel targets in cancer and other diseases.
Stanford researchers have engineered chimeric cytokine receptors that are expressed in therapeutic cells to enhance their activity and therapeutic potential.
Stem cells are generally influenced by a microenvironmental niche, typically comprised of epithelial and mesenchymal cells and extracellular substrates. Many attempts have been made to produce culture systems that mimic normal intestinal epithelial growth and differentiation.
Patients with celiac disease have a pathological reaction to gluten and have either HLA-DQ2+ (90%) or HLA-DQ8+, but expression of these MHC class II haplotypes is not sufficient and other factors are necessary for the development of celiac sprue.